Sainty Pharma: The company's products are planned to be selected for the national organizations' centralized procurement drug follow-up purchase.

Sino Biopharmaceutical announced that its wholly-owned subsidiary, Chengdu Sino Biopharmaceutical Co., Ltd., participated in the new round of national centralized drug procurement organized by the government from the first to eighth batch. The company's products Acetyl Octreotide Injection, Acetyl Atosiban Injection, Somatostatin Injection, along with the newly selected products Thymopentin Injection and Exenatide Injection were all proposed to be selected in this new round of procurement.